Very good clinical results for Paclical®
Very good clinical results for Paclical®
The pharmaceutical company Oasmia Pharmaceutical has recently concluded a phase I/II study on cancer patients with its product Paclical®. The purpose was investigation of different doses and side-effects. The results fulfilled all the company's expectations.
Cancer is one of the most common diseases. WHO reports that 11 million people are diagnosed with cancer each year. There is a constant need for new drugs and treatments. Oasmia develops pharmaceuticals and opens up for new methods in cancer treatment.
During the recent years, Oasmia have carried out a study on cancer patients. The results will be presented shortly.
The company will initiate Phase III-studies on patients starting the third quarter 2007.
